A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-02-15

AUTHORS

Jiayi Huang, Rekha Chaudhary, Adam L. Cohen, Karen Fink, Samuel Goldlust, John Boockvar, Prakash Chinnaiyan, Leping Wan, Stephen Marcus, Jian L. Campian

ABSTRACT

PURPOSE: Preclinical studies have suggested promising activity for the combination of disulfiram and copper (DSF/Cu) against glioblastoma (GBM) including re-sensitization to temozolomide (TMZ). A previous phase I study demonstrated the safety of combining DSF/Cu with adjuvant TMZ for newly diagnosed GBM. This phase II study aimed to estimate the potential effectiveness of DSF/Cu to re-sensitize recurrent GBM to TMZ. METHODS: This open-label, single-arm phase II study treated recurrent TMZ-resistant GBM patients with standard monthly TMZ plus concurrent daily DSF 80 mg PO TID and Cu 1.5 mg PO TID. Eligible patients must have progressed after standard chemoradiotherapy and within 3 months of the last dose of TMZ. Known isocitrate dehydrogenase (IDH) mutant or secondary GBMs were excluded. The primary endpoint was objective response rate (ORR), and the secondary endpoints included progression-free survival (PFS), overall survival (OS), clinical benefit (response or stable disease for at least 6 months), and safety. RESULTS: From March 2017 to January 2018, 23 recurrent TMZ-resistant GBM patients were enrolled across seven centers, and 21 patients were evaluable for response. The median duration of DSF/Cu was 1.6 cycles (range: 0.1-12.0). The ORR was 0%, but 14% had clinical benefit. Median PFS was 1.7 months, and median OS was 7.1 months. Only one patient (4%) had dose-limiting toxicity (grade three elevated alanine transaminase). CONCLUSIONS: Addition of DSF/Cu to TMZ for TMZ-resistant IDH-wild type GBM appears well tolerated but has limited activity for unselected population. More... »

PAGES

1-8

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11060-019-03125-y

DOI

http://dx.doi.org/10.1007/s11060-019-03125-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1112158640

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30771200


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Washington University in St. Louis", 
          "id": "https://www.grid.ac/institutes/grid.4367.6", 
          "name": [
            "Washington University School of Medicine, St. Louis, MO, USA", 
            "Department of Radiation Oncology, Center for Advanced Medicine, Washington University School of Medicine, 4921 Parkview Place, Campus Box #8224, 63110, St. Louis, MO, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Huang", 
        "givenName": "Jiayi", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Cincinnati", 
          "id": "https://www.grid.ac/institutes/grid.24827.3b", 
          "name": [
            "University of Cincinnati College of Medicine, Cincinnati, OH, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chaudhary", 
        "givenName": "Rekha", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Utah Health Care", 
          "id": "https://www.grid.ac/institutes/grid.412722.0", 
          "name": [
            "Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cohen", 
        "givenName": "Adam L.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Baylor University Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.411588.1", 
          "name": [
            "Baylor University Medical Center, Dallas, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fink", 
        "givenName": "Karen", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hackensack University Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.239835.6", 
          "name": [
            "Hackensack University Medical Center, Hackensack, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Goldlust", 
        "givenName": "Samuel", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Lenox Hill Hospital", 
          "id": "https://www.grid.ac/institutes/grid.415895.4", 
          "name": [
            "Lenox Hill Hospital, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Boockvar", 
        "givenName": "John", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Beaumont Health", 
          "id": "https://www.grid.ac/institutes/grid.461921.9", 
          "name": [
            "Beaumont Health, Royal Oak, MI, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chinnaiyan", 
        "givenName": "Prakash", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Washington University in St. Louis", 
          "id": "https://www.grid.ac/institutes/grid.4367.6", 
          "name": [
            "Washington University School of Medicine, St. Louis, MO, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wan", 
        "givenName": "Leping", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Cantex Pharmaceuticals, Weston, FL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Marcus", 
        "givenName": "Stephen", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Washington University in St. Louis", 
          "id": "https://www.grid.ac/institutes/grid.4367.6", 
          "name": [
            "Washington University School of Medicine, St. Louis, MO, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Campian", 
        "givenName": "Jian L.", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-15-1798", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005647230"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.18.8417", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006555828"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.16.3055", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010751135"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.18632/oncotarget.707", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012229587"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11060-016-2104-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013624075", 
          "https://doi.org/10.1007/s11060-016-2104-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.2012.442", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025902917", 
          "https://doi.org/10.1038/bjc.2012.442"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1634/theoncologist.2014-0424", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029999843"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/clpt.1984.213", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030661864", 
          "https://doi.org/10.1038/clpt.1984.213"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.18632/oncotarget.604", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034907070"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.19.8721", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042965400"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.26.3541", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043187529"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1308573", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048225580"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2013.49.6968", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051461825"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3332/ecancer.2014.485", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051728454"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-14-2391", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063215740"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1999.17.8.2572", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074549881"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1707358", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092706366"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11060-018-2775-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100671337", 
          "https://doi.org/10.1007/s11060-018-2775-y"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-02-15", 
    "datePublishedReg": "2019-02-15", 
    "description": "PURPOSE: Preclinical studies have suggested promising activity for the combination of disulfiram and copper (DSF/Cu) against glioblastoma (GBM) including re-sensitization to temozolomide (TMZ). A previous phase I study demonstrated the safety of combining DSF/Cu with adjuvant TMZ for newly diagnosed GBM. This phase II study aimed to estimate the potential effectiveness of DSF/Cu to re-sensitize recurrent GBM to TMZ.\nMETHODS: This open-label, single-arm phase II study treated recurrent TMZ-resistant GBM patients with standard monthly TMZ plus concurrent daily DSF 80\u00a0mg PO TID and Cu 1.5\u00a0mg PO TID. Eligible patients must have progressed after standard chemoradiotherapy and within 3\u00a0months of the last dose of TMZ. Known isocitrate dehydrogenase (IDH) mutant or secondary GBMs were excluded. The primary endpoint was objective response rate (ORR), and the secondary endpoints included progression-free survival (PFS), overall survival (OS), clinical benefit (response or stable disease for at least 6\u00a0months), and safety.\nRESULTS: From March 2017 to January 2018, 23 recurrent TMZ-resistant GBM patients were enrolled across seven centers, and 21 patients were evaluable for response. The median duration of DSF/Cu was 1.6 cycles (range: 0.1-12.0). The ORR was 0%, but 14% had clinical benefit. Median PFS was 1.7\u00a0months, and median OS was 7.1\u00a0months. Only one patient (4%) had dose-limiting toxicity (grade three elevated alanine transaminase).\nCONCLUSIONS: Addition of DSF/Cu to TMZ for TMZ-resistant IDH-wild type GBM appears well tolerated but has limited activity for unselected population.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s11060-019-03125-y", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094205", 
        "issn": [
          "0167-594X", 
          "1573-7373"
        ], 
        "name": "Journal of Neuro-Oncology", 
        "type": "Periodical"
      }
    ], 
    "name": "A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma", 
    "pagination": "1-8", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "e791c162ebbeab66faba18fdaa5d1894829f2f4142ce80a14dcc8fdffb4dd42c"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30771200"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309335"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11060-019-03125-y"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1112158640"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11060-019-03125-y", 
      "https://app.dimensions.ai/details/publication/pub.1112158640"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T09:07", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000337_0000000337/records_37570_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs11060-019-03125-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11060-019-03125-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11060-019-03125-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11060-019-03125-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11060-019-03125-y'


 

This table displays all metadata directly associated to this object as RDF triples.

195 TRIPLES      21 PREDICATES      44 URIs      18 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11060-019-03125-y schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N7d315e75d5d0448eac1285b3558cc1ad
4 schema:citation sg:pub.10.1007/s11060-016-2104-2
5 sg:pub.10.1007/s11060-018-2775-y
6 sg:pub.10.1038/bjc.2012.442
7 sg:pub.10.1038/clpt.1984.213
8 https://doi.org/10.1056/nejmoa1308573
9 https://doi.org/10.1056/nejmoa1707358
10 https://doi.org/10.1158/0008-5472.can-14-2391
11 https://doi.org/10.1158/1078-0432.ccr-15-1798
12 https://doi.org/10.1200/jco.1999.17.8.2572
13 https://doi.org/10.1200/jco.2008.16.3055
14 https://doi.org/10.1200/jco.2008.18.8417
15 https://doi.org/10.1200/jco.2008.19.8721
16 https://doi.org/10.1200/jco.2009.26.3541
17 https://doi.org/10.1200/jco.2013.49.6968
18 https://doi.org/10.1634/theoncologist.2014-0424
19 https://doi.org/10.18632/oncotarget.604
20 https://doi.org/10.18632/oncotarget.707
21 https://doi.org/10.3332/ecancer.2014.485
22 schema:datePublished 2019-02-15
23 schema:datePublishedReg 2019-02-15
24 schema:description PURPOSE: Preclinical studies have suggested promising activity for the combination of disulfiram and copper (DSF/Cu) against glioblastoma (GBM) including re-sensitization to temozolomide (TMZ). A previous phase I study demonstrated the safety of combining DSF/Cu with adjuvant TMZ for newly diagnosed GBM. This phase II study aimed to estimate the potential effectiveness of DSF/Cu to re-sensitize recurrent GBM to TMZ. METHODS: This open-label, single-arm phase II study treated recurrent TMZ-resistant GBM patients with standard monthly TMZ plus concurrent daily DSF 80 mg PO TID and Cu 1.5 mg PO TID. Eligible patients must have progressed after standard chemoradiotherapy and within 3 months of the last dose of TMZ. Known isocitrate dehydrogenase (IDH) mutant or secondary GBMs were excluded. The primary endpoint was objective response rate (ORR), and the secondary endpoints included progression-free survival (PFS), overall survival (OS), clinical benefit (response or stable disease for at least 6 months), and safety. RESULTS: From March 2017 to January 2018, 23 recurrent TMZ-resistant GBM patients were enrolled across seven centers, and 21 patients were evaluable for response. The median duration of DSF/Cu was 1.6 cycles (range: 0.1-12.0). The ORR was 0%, but 14% had clinical benefit. Median PFS was 1.7 months, and median OS was 7.1 months. Only one patient (4%) had dose-limiting toxicity (grade three elevated alanine transaminase). CONCLUSIONS: Addition of DSF/Cu to TMZ for TMZ-resistant IDH-wild type GBM appears well tolerated but has limited activity for unselected population.
25 schema:genre research_article
26 schema:inLanguage en
27 schema:isAccessibleForFree false
28 schema:isPartOf sg:journal.1094205
29 schema:name A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma
30 schema:pagination 1-8
31 schema:productId N118ffe9d87434603a818ff2861e6b7b0
32 N3a860fcaca4745f999dc8707248f6d7f
33 N6d9778d79e15461eae6764ac9ae2b16c
34 Nc96ec9ec46c1464089ff2812894fc9d6
35 Nfb160fa1899c4e7d989547bfa58665a7
36 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112158640
37 https://doi.org/10.1007/s11060-019-03125-y
38 schema:sdDatePublished 2019-04-11T09:07
39 schema:sdLicense https://scigraph.springernature.com/explorer/license/
40 schema:sdPublisher N1479864af70c47269e1352bc7dedd6af
41 schema:url https://link.springer.com/10.1007%2Fs11060-019-03125-y
42 sgo:license sg:explorer/license/
43 sgo:sdDataset articles
44 rdf:type schema:ScholarlyArticle
45 N03a1ac5cd8cf4cdbb891ee326357b641 rdf:first N16d97d0fcb5a4691aedab042372194c1
46 rdf:rest N1759d1ae1fe345628d153ed3445d7627
47 N118ffe9d87434603a818ff2861e6b7b0 schema:name nlm_unique_id
48 schema:value 8309335
49 rdf:type schema:PropertyValue
50 N123f24ee21a642ada8b3a5833da0ee96 schema:affiliation https://www.grid.ac/institutes/grid.412722.0
51 schema:familyName Cohen
52 schema:givenName Adam L.
53 rdf:type schema:Person
54 N124fb52f60354e218bb629d278683aa8 rdf:first N123f24ee21a642ada8b3a5833da0ee96
55 rdf:rest Nda7775ce9fb749e2b0e1649e7e4dee03
56 N1479864af70c47269e1352bc7dedd6af schema:name Springer Nature - SN SciGraph project
57 rdf:type schema:Organization
58 N16d97d0fcb5a4691aedab042372194c1 schema:affiliation https://www.grid.ac/institutes/grid.239835.6
59 schema:familyName Goldlust
60 schema:givenName Samuel
61 rdf:type schema:Person
62 N1759d1ae1fe345628d153ed3445d7627 rdf:first Nbfac058632824f7e9b209578eeb7377b
63 rdf:rest N9b0fe09ed05b4857a3da16255bd059f2
64 N1b371f1b881b4a638f8f8f1ddc4753ab schema:name Cantex Pharmaceuticals, Weston, FL, USA
65 rdf:type schema:Organization
66 N1c71b47ca4bf4401bd96fd413a4f27fe schema:affiliation https://www.grid.ac/institutes/grid.4367.6
67 schema:familyName Campian
68 schema:givenName Jian L.
69 rdf:type schema:Person
70 N24882f0510d24bc586647877688e24ad schema:affiliation N1b371f1b881b4a638f8f8f1ddc4753ab
71 schema:familyName Marcus
72 schema:givenName Stephen
73 rdf:type schema:Person
74 N3a860fcaca4745f999dc8707248f6d7f schema:name readcube_id
75 schema:value e791c162ebbeab66faba18fdaa5d1894829f2f4142ce80a14dcc8fdffb4dd42c
76 rdf:type schema:PropertyValue
77 N53f660cc0fc64651924cecf94b94bced schema:affiliation https://www.grid.ac/institutes/grid.24827.3b
78 schema:familyName Chaudhary
79 schema:givenName Rekha
80 rdf:type schema:Person
81 N57243e4f48354bbfb9c80154055237de rdf:first Na2050d43718f49e48fa23173b8e9bd8b
82 rdf:rest Na3acf4334b5c47a1b71c159b1dbd70fb
83 N63bd2704246c46b28d3843b032b455a2 schema:affiliation https://www.grid.ac/institutes/grid.4367.6
84 schema:familyName Huang
85 schema:givenName Jiayi
86 rdf:type schema:Person
87 N6d9778d79e15461eae6764ac9ae2b16c schema:name doi
88 schema:value 10.1007/s11060-019-03125-y
89 rdf:type schema:PropertyValue
90 N7d315e75d5d0448eac1285b3558cc1ad rdf:first N63bd2704246c46b28d3843b032b455a2
91 rdf:rest Nbe67e10af7ff435f9b2a93b8ac62f1a9
92 N9b0fe09ed05b4857a3da16255bd059f2 rdf:first Na51e2f2609a340d586497635976b8d48
93 rdf:rest N57243e4f48354bbfb9c80154055237de
94 Na2050d43718f49e48fa23173b8e9bd8b schema:affiliation https://www.grid.ac/institutes/grid.4367.6
95 schema:familyName Wan
96 schema:givenName Leping
97 rdf:type schema:Person
98 Na3acf4334b5c47a1b71c159b1dbd70fb rdf:first N24882f0510d24bc586647877688e24ad
99 rdf:rest Nfb31be43f46c426d8c87fcf3744c727d
100 Na51e2f2609a340d586497635976b8d48 schema:affiliation https://www.grid.ac/institutes/grid.461921.9
101 schema:familyName Chinnaiyan
102 schema:givenName Prakash
103 rdf:type schema:Person
104 Nbe67e10af7ff435f9b2a93b8ac62f1a9 rdf:first N53f660cc0fc64651924cecf94b94bced
105 rdf:rest N124fb52f60354e218bb629d278683aa8
106 Nbfac058632824f7e9b209578eeb7377b schema:affiliation https://www.grid.ac/institutes/grid.415895.4
107 schema:familyName Boockvar
108 schema:givenName John
109 rdf:type schema:Person
110 Nc96ec9ec46c1464089ff2812894fc9d6 schema:name pubmed_id
111 schema:value 30771200
112 rdf:type schema:PropertyValue
113 Nda7775ce9fb749e2b0e1649e7e4dee03 rdf:first Nf96e40bb6bf54d148e65a682d6a1c7f9
114 rdf:rest N03a1ac5cd8cf4cdbb891ee326357b641
115 Nf96e40bb6bf54d148e65a682d6a1c7f9 schema:affiliation https://www.grid.ac/institutes/grid.411588.1
116 schema:familyName Fink
117 schema:givenName Karen
118 rdf:type schema:Person
119 Nfb160fa1899c4e7d989547bfa58665a7 schema:name dimensions_id
120 schema:value pub.1112158640
121 rdf:type schema:PropertyValue
122 Nfb31be43f46c426d8c87fcf3744c727d rdf:first N1c71b47ca4bf4401bd96fd413a4f27fe
123 rdf:rest rdf:nil
124 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
125 schema:name Medical and Health Sciences
126 rdf:type schema:DefinedTerm
127 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
128 schema:name Clinical Sciences
129 rdf:type schema:DefinedTerm
130 sg:journal.1094205 schema:issn 0167-594X
131 1573-7373
132 schema:name Journal of Neuro-Oncology
133 rdf:type schema:Periodical
134 sg:pub.10.1007/s11060-016-2104-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013624075
135 https://doi.org/10.1007/s11060-016-2104-2
136 rdf:type schema:CreativeWork
137 sg:pub.10.1007/s11060-018-2775-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1100671337
138 https://doi.org/10.1007/s11060-018-2775-y
139 rdf:type schema:CreativeWork
140 sg:pub.10.1038/bjc.2012.442 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025902917
141 https://doi.org/10.1038/bjc.2012.442
142 rdf:type schema:CreativeWork
143 sg:pub.10.1038/clpt.1984.213 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030661864
144 https://doi.org/10.1038/clpt.1984.213
145 rdf:type schema:CreativeWork
146 https://doi.org/10.1056/nejmoa1308573 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048225580
147 rdf:type schema:CreativeWork
148 https://doi.org/10.1056/nejmoa1707358 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092706366
149 rdf:type schema:CreativeWork
150 https://doi.org/10.1158/0008-5472.can-14-2391 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063215740
151 rdf:type schema:CreativeWork
152 https://doi.org/10.1158/1078-0432.ccr-15-1798 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005647230
153 rdf:type schema:CreativeWork
154 https://doi.org/10.1200/jco.1999.17.8.2572 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074549881
155 rdf:type schema:CreativeWork
156 https://doi.org/10.1200/jco.2008.16.3055 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010751135
157 rdf:type schema:CreativeWork
158 https://doi.org/10.1200/jco.2008.18.8417 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006555828
159 rdf:type schema:CreativeWork
160 https://doi.org/10.1200/jco.2008.19.8721 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042965400
161 rdf:type schema:CreativeWork
162 https://doi.org/10.1200/jco.2009.26.3541 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043187529
163 rdf:type schema:CreativeWork
164 https://doi.org/10.1200/jco.2013.49.6968 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051461825
165 rdf:type schema:CreativeWork
166 https://doi.org/10.1634/theoncologist.2014-0424 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029999843
167 rdf:type schema:CreativeWork
168 https://doi.org/10.18632/oncotarget.604 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034907070
169 rdf:type schema:CreativeWork
170 https://doi.org/10.18632/oncotarget.707 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012229587
171 rdf:type schema:CreativeWork
172 https://doi.org/10.3332/ecancer.2014.485 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051728454
173 rdf:type schema:CreativeWork
174 https://www.grid.ac/institutes/grid.239835.6 schema:alternateName Hackensack University Medical Center
175 schema:name Hackensack University Medical Center, Hackensack, NJ, USA
176 rdf:type schema:Organization
177 https://www.grid.ac/institutes/grid.24827.3b schema:alternateName University of Cincinnati
178 schema:name University of Cincinnati College of Medicine, Cincinnati, OH, USA
179 rdf:type schema:Organization
180 https://www.grid.ac/institutes/grid.411588.1 schema:alternateName Baylor University Medical Center
181 schema:name Baylor University Medical Center, Dallas, TX, USA
182 rdf:type schema:Organization
183 https://www.grid.ac/institutes/grid.412722.0 schema:alternateName University of Utah Health Care
184 schema:name Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
185 rdf:type schema:Organization
186 https://www.grid.ac/institutes/grid.415895.4 schema:alternateName Lenox Hill Hospital
187 schema:name Lenox Hill Hospital, New York, NY, USA
188 rdf:type schema:Organization
189 https://www.grid.ac/institutes/grid.4367.6 schema:alternateName Washington University in St. Louis
190 schema:name Department of Radiation Oncology, Center for Advanced Medicine, Washington University School of Medicine, 4921 Parkview Place, Campus Box #8224, 63110, St. Louis, MO, USA
191 Washington University School of Medicine, St. Louis, MO, USA
192 rdf:type schema:Organization
193 https://www.grid.ac/institutes/grid.461921.9 schema:alternateName Beaumont Health
194 schema:name Beaumont Health, Royal Oak, MI, USA
195 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...